Cargando…
The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation
BACKGROUND: Diabetes is associated with premature death and a number of serious complications. The presence of comorbid depression makes these outcomes more likely and results in increased healthcare costs. The aim of this work was to assess the health economic outcomes associated with having both d...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259945/ https://www.ncbi.nlm.nih.gov/pubmed/28118838 http://dx.doi.org/10.1186/s12913-017-2003-z |
_version_ | 1782499308962054144 |
---|---|
author | Kearns, Ben Rafia, R. Leaviss, J. Preston, L. Brazier, J.E. Palmer, S. Ara, R. |
author_facet | Kearns, Ben Rafia, R. Leaviss, J. Preston, L. Brazier, J.E. Palmer, S. Ara, R. |
author_sort | Kearns, Ben |
collection | PubMed |
description | BACKGROUND: Diabetes is associated with premature death and a number of serious complications. The presence of comorbid depression makes these outcomes more likely and results in increased healthcare costs. The aim of this work was to assess the health economic outcomes associated with having both diabetes and depression, and assess the cost-effectiveness of potential policy changes to improve the care pathway: improved opportunistic screening for depression, collaborative care for depression treatment, and the combination of both. METHODS: A mathematical model of the care pathways experienced by people diagnosed with type-2 diabetes in England was developed. Both an NHS perspective and wider social benefits were considered. Evidence was taken from the published literature, identified via scoping and targeted searches. RESULTS: Compared with current practice, all three policies reduced both the time spent with depression and the number of diabetes-related complications experienced. The policies were associated with an improvement in quality of life, but with an increase in health care costs. In an incremental analysis, collaborative care dominated improved opportunistic screening. The incremental cost-effectiveness ratio (ICER) for collaborative care compared with current practice was £10,798 per QALY. Compared to collaborative care, the combined policy had an ICER of £68,017 per QALY. CONCLUSIONS: Policies targeted at identifying and treating depression early in patients with diabetes may lead to reductions in diabetes related complications and depression, which in turn increase life expectancy and improve health-related quality of life. Implementing collaborative care was cost-effective based on current national guidance in England. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12913-017-2003-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5259945 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-52599452017-01-26 The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation Kearns, Ben Rafia, R. Leaviss, J. Preston, L. Brazier, J.E. Palmer, S. Ara, R. BMC Health Serv Res Research Article BACKGROUND: Diabetes is associated with premature death and a number of serious complications. The presence of comorbid depression makes these outcomes more likely and results in increased healthcare costs. The aim of this work was to assess the health economic outcomes associated with having both diabetes and depression, and assess the cost-effectiveness of potential policy changes to improve the care pathway: improved opportunistic screening for depression, collaborative care for depression treatment, and the combination of both. METHODS: A mathematical model of the care pathways experienced by people diagnosed with type-2 diabetes in England was developed. Both an NHS perspective and wider social benefits were considered. Evidence was taken from the published literature, identified via scoping and targeted searches. RESULTS: Compared with current practice, all three policies reduced both the time spent with depression and the number of diabetes-related complications experienced. The policies were associated with an improvement in quality of life, but with an increase in health care costs. In an incremental analysis, collaborative care dominated improved opportunistic screening. The incremental cost-effectiveness ratio (ICER) for collaborative care compared with current practice was £10,798 per QALY. Compared to collaborative care, the combined policy had an ICER of £68,017 per QALY. CONCLUSIONS: Policies targeted at identifying and treating depression early in patients with diabetes may lead to reductions in diabetes related complications and depression, which in turn increase life expectancy and improve health-related quality of life. Implementing collaborative care was cost-effective based on current national guidance in England. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12913-017-2003-z) contains supplementary material, which is available to authorized users. BioMed Central 2017-01-24 /pmc/articles/PMC5259945/ /pubmed/28118838 http://dx.doi.org/10.1186/s12913-017-2003-z Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Kearns, Ben Rafia, R. Leaviss, J. Preston, L. Brazier, J.E. Palmer, S. Ara, R. The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation |
title | The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation |
title_full | The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation |
title_fullStr | The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation |
title_full_unstemmed | The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation |
title_short | The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation |
title_sort | cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in england: a model-based economic evaluation |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259945/ https://www.ncbi.nlm.nih.gov/pubmed/28118838 http://dx.doi.org/10.1186/s12913-017-2003-z |
work_keys_str_mv | AT kearnsben thecosteffectivenessofchangestothecarepathwayusedtoidentifydepressionandprovidetreatmentamongstpeoplewithdiabetesinenglandamodelbasedeconomicevaluation AT rafiar thecosteffectivenessofchangestothecarepathwayusedtoidentifydepressionandprovidetreatmentamongstpeoplewithdiabetesinenglandamodelbasedeconomicevaluation AT leavissj thecosteffectivenessofchangestothecarepathwayusedtoidentifydepressionandprovidetreatmentamongstpeoplewithdiabetesinenglandamodelbasedeconomicevaluation AT prestonl thecosteffectivenessofchangestothecarepathwayusedtoidentifydepressionandprovidetreatmentamongstpeoplewithdiabetesinenglandamodelbasedeconomicevaluation AT brazierje thecosteffectivenessofchangestothecarepathwayusedtoidentifydepressionandprovidetreatmentamongstpeoplewithdiabetesinenglandamodelbasedeconomicevaluation AT palmers thecosteffectivenessofchangestothecarepathwayusedtoidentifydepressionandprovidetreatmentamongstpeoplewithdiabetesinenglandamodelbasedeconomicevaluation AT arar thecosteffectivenessofchangestothecarepathwayusedtoidentifydepressionandprovidetreatmentamongstpeoplewithdiabetesinenglandamodelbasedeconomicevaluation AT kearnsben costeffectivenessofchangestothecarepathwayusedtoidentifydepressionandprovidetreatmentamongstpeoplewithdiabetesinenglandamodelbasedeconomicevaluation AT rafiar costeffectivenessofchangestothecarepathwayusedtoidentifydepressionandprovidetreatmentamongstpeoplewithdiabetesinenglandamodelbasedeconomicevaluation AT leavissj costeffectivenessofchangestothecarepathwayusedtoidentifydepressionandprovidetreatmentamongstpeoplewithdiabetesinenglandamodelbasedeconomicevaluation AT prestonl costeffectivenessofchangestothecarepathwayusedtoidentifydepressionandprovidetreatmentamongstpeoplewithdiabetesinenglandamodelbasedeconomicevaluation AT brazierje costeffectivenessofchangestothecarepathwayusedtoidentifydepressionandprovidetreatmentamongstpeoplewithdiabetesinenglandamodelbasedeconomicevaluation AT palmers costeffectivenessofchangestothecarepathwayusedtoidentifydepressionandprovidetreatmentamongstpeoplewithdiabetesinenglandamodelbasedeconomicevaluation AT arar costeffectivenessofchangestothecarepathwayusedtoidentifydepressionandprovidetreatmentamongstpeoplewithdiabetesinenglandamodelbasedeconomicevaluation |